MENU
IT | EUR
IT | EUR
-
- Tutte le centrifughe
- Centrifughe da banco
- Centrifughe da pavimento
- Centrifughe refrigerate
- Microcentrifughe
- Centrifughe multiuso
- Centrifughe ad alta velocità
- Ultracentrifughe
- Concentratore
- Prodotti IVD
- High-Speed and Ultracentrifuge Consumables
- Provette per centrifughe
- Piastre per centrifughe
- Gestione degli apparecchi
- Gestione di campioni e informazioni
-
- Tutte le pipette, i dispenser e i sistemi automatizzati per la manipolazione dei liquidi
- Pipette meccaniche
- Pipette elettroniche
- Pipette multicanale
- Pipette e dispenser a spostamento positivo
- Puntali per pipette
- Dispenser per flaconi
- Controller per pipette
- Accessori per dispenser e pipette
- Pipettaggio automatico
- Consumabili per l'automazione
- Accessori per l'automazione
- Servizi di assistenza per dispenser e pipette
Sorry, we couldn't find anything on our website containing your search term.
Sorry, we couldn't find anything on our website containing your search term.
Vaccine Research Discovered
Well thought-out tools for pharmaceutical and biotech laboratories
Read more
Read less
STRONG GROWING VACCINES
Protein subunit vaccines
Protein subunit vaccines (e.g., for influenza, hepatitis B and C) are a proven strategy for decades and still today in the spotlight for pandemic management.
➕ Require no production of the whole pathogen because the vaccine consists of immunogenic viral or bacterial fragments generated by recombinant protein techniques. Since non-pathogenic, they are considered as safe. Multiple expression systems for antigenic protein components such as yeast, bacteria, insect, mammalian, and plant cells, allow the production of large quantities and to address unmet needs.
➖ Establishment of a proper scale-up of antigen production can be a major constraint. Several booster doses and adjuvants are needed.
Protein subunit vaccines (e.g., for influenza, hepatitis B and C) are a proven strategy for decades and still today in the spotlight for pandemic management.
➕ Require no production of the whole pathogen because the vaccine consists of immunogenic viral or bacterial fragments generated by recombinant protein techniques. Since non-pathogenic, they are considered as safe. Multiple expression systems for antigenic protein components such as yeast, bacteria, insect, mammalian, and plant cells, allow the production of large quantities and to address unmet needs.
➖ Establishment of a proper scale-up of antigen production can be a major constraint. Several booster doses and adjuvants are needed.
Virus-like particle vaccines
Virus-like particle vaccines are self-assembled viral structural proteins that mimic the native virus. This feature enables to trigger strong immune responses.
➕ Lacking the viral genome, the safety profile is excellent. The production is scalable and safe as no living virus or inactivation steps are involved.
➖ The particle assembly is sometimes challenging, the manufacturing process complicated.
Virus-like particle vaccines are self-assembled viral structural proteins that mimic the native virus. This feature enables to trigger strong immune responses.
➕ Lacking the viral genome, the safety profile is excellent. The production is scalable and safe as no living virus or inactivation steps are involved.
➖ The particle assembly is sometimes challenging, the manufacturing process complicated.
IMPROVE YOUR RECOMBINANT PROTEIN VACCINE DISCOVERY
*All products are for Research Use Only (RUO).